• MJHLS Brand Logo

© 2026 MJH Life Sciences™ and The Center for Biosimilars - Biosimilars, Health Economics & Insights. All rights reserved.

Biosimilar Denosumab Shows Cost-Effectiveness Over Bisphosphonates in PMO

Biosimilar Denosumab Shows Cost-Effectiveness Over Bisphosphonates in PMO

August 04, 2026

Biosimilar denosumab cleared a $150,000 per QALY cost-effectiveness threshold against bisphosphonates for high-risk PMO, but not always at $100,000.

Biosimilars Round Up: July 2026

August 04, 2026

Denosumab Biosimilar KN012 Matches Reference Drug in Phase 3 Osteoporosis Trial

July 30, 2026

India's Anti-VEGF Biosimilars Cut Costs, Expand Access

July 30, 2026

Eculizumab Biosimilar Shows Durable Benefit in Long-Term aHUS

July 29, 2026

Featured Content

Biosimilar Bills Gain Steam in Congress, But Key Reforms Still Wait

July 23rd 2026

By Skylar Jeremias

Article

Congress fast-tracks biosimilar bills to cut drug and insulin costs, while patent, rebate, and reimbursement roadblocks still stall competition.

Aflibercept Biosimilar SB15 Shows Real-World Efficacy Across Retinal Diseases

July 22nd 2026

By Pearl Steinzor

Article

Aflibercept biosimilar SB15 improved retinal anatomy while preserving vision in both treatment-naïve and switching patients with nAMD, RVO, and DME.

Biosimilar Ranibizumab Performs on Par With Innovator Drug Across Retinal Diseases

July 21st 2026

By Pearl Steinzor

Article

Nearly 5000 eyes and nearly 21,000 injections show comparable vision, anatomical, and safety outcomes between biosimilar ranibizumab and the innovator drug.

Real-World Natalizumab Biosimilar Switch Reduced Treatment Satisfaction Despite Stable Outcomes

July 20th 2026

By Brooke McCormick

Article

Real-world natalizumab biosimilar switching preserved relapsing-remitting MS outcomes but lowered treatment satisfaction, likely due to a nocebo effect.

Romosozumab Biosimilar Matches Reference in Functional Testing Despite Disulfide Differences

July 16th 2026

By Brooke McCormick

Article

A romosozumab biosimilar showed comparable sclerostin binding and bone-signaling potency to the reference product despite disulfide isoform differences.

FDA Accepts Sandoz Generic Tirzepatide Applications Amid Biosimilar Development Gap

July 13th 2026

By Skylar Jeremias

Article

Sandoz moves toward US generic tirzepatide autoinjectors as FDA reviews ANDAs, signaling future GLP‑1 access amid patent and biosimilar gaps.

Anti-VEGF Biosimilars Match Reference Drug in Indian Retinal Disease Care

July 9th 2026

By Skylar Jeremias

Article

Biosimilar anti-VEGF agents matched the reference ranibizumab in vision outcomes and safety across retinal diseases in India, at a lower cost.

Rituximab Biosimilar Reached 75% Remission, Matched Innovator in Membranous Nephropathy

July 8th 2026

By Skylar Jeremias

Article

Real-world data shows rituximab biosimilars for membranous nephropathy match remission rates, cut costs, and expand treatment options.

Biosimilar ABP 654 Maintains Efficacy, Safety After Repeated Switching From Ustekinumab

July 7th 2026

By Skylar Jeremias

Article

Trial data show switching between ABP 654 and reference ustekinumab maintains similar psoriasis control, safety, and immunogenicity, supporting FDA interchangeability confidence.

Biosimilar Denosumab Matches Reference Drug for Bone Density in Chinese Women

July 6th 2026

By Skylar Jeremias

Article

Phase 3 data show denosumab biosimilar KN012 matches Prolia for BMD gains and safety, potentially expanding affordable osteoporosis care.